文献速递临床试验与 GCP

基于CCL14识别的脓毒症相关急性肾损伤亚型混合血液净化的疗效:单中心随机对照临床试验研究方案

Efficacy of hybrid blood purification for SA-AKI subtypes identified by CCL14: study protocol for a single-centre randomized controlled clinical trial.
PubMed 文献 · Trials · 2025-08-26

本研究为单中心盲法随机对照试验,纳入ICU脓毒症相关急性肾损伤(SA-AKI)患者,检测尿CCL14浓度后随机分为CVVH组和混合血液净化(HBP)组。主要结局为入组后30天全因死亡率,旨在探讨HBP对CCL14识别亚型患者30天全因死亡率的影响,为临床实践提供研究证据。

要点

  • 尿CCL14高水平可早期识别持续性SA-AKI危重患者。
  • HBP组接受HA380血液灌流滤器联合CVVH治疗,CVVH组仅使用AN69 ST100滤器行CVVH。
  • 主要结局为入组后30天全因死亡率,次要结局包括90天全因死亡率、90天内CKD发生率等。

核心结论

  • 作者假设混合血液净化(HBP)治疗对CCL14识别的SA-AKI患者具有有益作用,本研究旨在探讨HBP对CCL14识别亚型SA-AKI患者30天全因死亡率的影响,为确定持续性严重SA-AKI患者的最佳治疗方式提供研究证据。

研究设计与样本

  • 单中心、盲法、随机对照临床试验,患者入ICU后采集血尿样本检测尿CCL14浓度,随后随机分为CVVH组和HBP组。
  • HBP组使用HA380血液灌流滤器(Jafron,中国)行血液灌流(HP)联合AN69 ST100血滤器(Baxter,美国)行CVVH;CVVH组仅使用AN69 ST100血滤器(Baxter,美国)选择CVVH模式行连续性肾脏替代治疗(CRRT)。
  • 试验注册于中国临床试验注册中心(ChiCTR),注册号ChiCTR2400093572,注册日期2024年12月9日。

主要发现

  • 主要结局为入组后30天全因死亡率;次要结局包括90天全因死亡率、90天内慢性肾脏病(CKD)发生率、入组后72小时肾功能变化。
  • 次要结局还包括内毒素水平变化、凝血功能参数变化、炎症因子水平变化、血浆内皮屏障相关指标变化、血流动力学参数变化。
  • 次要结局还包括SOFA评分变化、Apache II评分变化、住院期间肾脏替代治疗(KRT)时长、机械通气时长、ICU住院时长及住院时长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a commonly encountered complex heterogeneous syndrome in critically ill patients with sepsis. Under the interaction of genotype and pathogenic factors, SA-AKI can lead to various clinical phenotypes and subphenotypes, and this heterogeneity complicates the assessment of the efficacy of treatment measures for sepsis in clinical trials. Early identification of SA-AKI high-risk patients with specific subphenotypes and timely implementation of supportive treatments may improve adverse outcomes for these patients. High levels of C-C motif chemokine ligand 14 (CCL14) serve as a biomarker that can early identify critically ill patients with persistent SA-AKI. However, the effects of different supportive treatment strategies on the prognosis of SA-AKI patients identified by CCL14 remain unclear. We hypothesize that integrated blood purification (HBP) therapy has a beneficial effect in the treatment of SA-AKI identified by CCL14. METHODS: This is a single-center, blinded, randomized controlled trial. After the patients were admitted to the ICU, blood and urine samples were taken, and the urine CCL14 concentration was measured. Subsequently, they were randomly assigned to the continuous veno-venous hemofiltration (CVVH) group and the hybrid blood purification (HBP) group. The HBP group received blood hemoperfusion (HP) treatment using the HA380 hemoperfusion filter (Jafron, China) and CVVH treatment using the AN69 ST100 blood filter (Baxter, USA). The CVVH group used only the AN69 ST100 blood filter (Baxter, USA) and selected the CVVH mode for continuous renal replacement therapy (CRRT). The primary outcome was the all-cause mortality rate at 30 days after enrollment. The secondary outcomes included the all-cause mortality rate at 90 days, the incidence of chronic kidney disease (CKD) within 90 days, changes in kidney function 72 h after enrollment, variations in endotoxin levels, changes in coagulation function parameters, alterations in inflammatory factor levels, changes in plasma endothelial barrier-related indicators, variations in hemodynamic parameters, changes in SOFA (Sequential (Sepsis-related) Organ Failure Assessment) score, changes in Apache II score, duration of kidney replacement therapy (KRT) during hospitalization, duration of mechanical ventilation, duration of stay in ICU, and duration of stay in hospital. DISCUSSION: This study aims to explore the impact of the HBP therapy on the 30-day all-cause mortality rate of patients with SA-AKI subtypes recognized by CCL14, providing relatively reliable research evidence for determining the optimal treatment approach for patients with persistent severe SA-AKI in clinical practice. TRIAL REGISTRATION: Chinese Clinical Trial Registry (CHICTR), ChiCTR2400093572. Registered on 9 December 2024, https://www.chictr.org.cn/showproj.html?proj=241688.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Shi K, Jiang W, Song L, et al. Efficacy of hybrid blood purification for SA-AKI subtypes identified by CCL14: study protocol for a single-centre randomized controlled clinical trial. Trials. 2025. PMID: 40859313. doi:10.1186/s13063-025-09058-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。